These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 21612343)

  • 1. Validation of membrane vesicle-based breast cancer resistance protein and multidrug resistance protein 2 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.
    Elsby R; Smith V; Fox L; Stresser D; Butters C; Sharma P; Surry DD
    Xenobiotica; 2011 Sep; 41(9):764-83. PubMed ID: 21612343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-activity p-glycoprotein, multidrug resistance protein 2, and breast cancer resistance protein membrane vesicles prepared from transiently transfected human embryonic kidney 293-epstein-barr virus nuclear antigen cells.
    Karlsson JE; Heddle C; Rozkov A; Rotticci-Mulder J; Tuvesson O; Hilgendorf C; Andersson TB
    Drug Metab Dispos; 2010 Apr; 38(4):705-14. PubMed ID: 20071452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
    Dahan A; Amidon GL
    Am J Physiol Gastrointest Liver Physiol; 2009 Aug; 297(2):G371-7. PubMed ID: 19541926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zinc finger nuclease-mediated gene knockout results in loss of transport activity for P-glycoprotein, BCRP, and MRP2 in Caco-2 cells.
    Sampson KE; Brinker A; Pratt J; Venkatraman N; Xiao Y; Blasberg J; Steiner T; Bourner M; Thompson DC
    Drug Metab Dispos; 2015 Feb; 43(2):199-207. PubMed ID: 25388687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor.
    Yamada A; Maeda K; Kamiyama E; Sugiyama D; Kondo T; Shiroyanagi Y; Nakazawa H; Okano T; Adachi M; Schuetz JD; Adachi Y; Hu Z; Kusuhara H; Sugiyama Y
    Drug Metab Dispos; 2007 Dec; 35(12):2166-76. PubMed ID: 17823233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.
    Te Brake LH; Russel FG; van den Heuvel JJ; de Knegt GJ; de Steenwinkel JE; Burger DM; Aarnoutse RE; Koenderink JB
    Tuberculosis (Edinb); 2016 Jan; 96():150-7. PubMed ID: 26682943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone.
    Lagas JS; van der Kruijssen CM; van de Wetering K; Beijnen JH; Schinkel AH
    Drug Metab Dispos; 2009 Jan; 37(1):129-36. PubMed ID: 18845662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
    Elsby R; Martin P; Surry D; Sharma P; Fenner K
    Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
    Pedersen JM; Matsson P; Bergström CA; Norinder U; Hoogstraate J; Artursson P
    J Med Chem; 2008 Jun; 51(11):3275-87. PubMed ID: 18457386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the role of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance-associated protein 4 (MRP4/ABCC4) in the urinary excretion of sulfate and glucuronide metabolites of edaravone (MCI-186; 3-methyl-1-phenyl-2-pyrazolin-5-one).
    Mizuno N; Takahashi T; Kusuhara H; Schuetz JD; Niwa T; Sugiyama Y
    Drug Metab Dispos; 2007 Nov; 35(11):2045-52. PubMed ID: 17682070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein.
    Huang L; Wang Y; Grimm S
    Drug Metab Dispos; 2006 May; 34(5):738-42. PubMed ID: 16415124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of cyclosporin a with breast cancer resistance protein.
    Xia CQ; Liu N; Miwa GT; Gan LS
    Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: a strategy to assess the interaction of a new chemical entity with P-gp, BCRP, and MRP2.
    Mease K; Sane R; Podila L; Taub ME
    J Pharm Sci; 2012 May; 101(5):1888-97. PubMed ID: 22359351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel understanding of ABC transporters ABCB1/MDR/P-glycoprotein, ABCC2/MRP2, and ABCG2/BCRP in colorectal pathophysiology.
    Andersen V; Svenningsen K; Knudsen LA; Hansen AK; Holmskov U; Stensballe A; Vogel U
    World J Gastroenterol; 2015 Nov; 21(41):11862-76. PubMed ID: 26557010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of SAGE Mdr1a (P-gp), Bcrp, and Mrp2 knockout rats using loperamide, paclitaxel, sulfasalazine, and carboxydichlorofluorescein pharmacokinetics.
    Zamek-Gliszczynski MJ; Bedwell DW; Bao JQ; Higgins JW
    Drug Metab Dispos; 2012 Sep; 40(9):1825-33. PubMed ID: 22711747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.
    Lempers VJ; van den Heuvel JJ; Russel FG; Aarnoutse RE; Burger DM; Brüggemann RJ; Koenderink JB
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3372-9. PubMed ID: 27001813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug-drug interaction to support regulatory submissions.
    Sharma P; Holmes VE; Elsby R; Lambert C; Surry D
    Xenobiotica; 2010 Jan; 40(1):24-37. PubMed ID: 19919292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro risk assessment of AZD9056 perpetrating a transporter-mediated drug-drug interaction with methotrexate.
    Elsby R; Fox L; Stresser D; Layton M; Butters C; Sharma P; Smith V; Surry D
    Eur J Pharm Sci; 2011 May; 43(1-2):41-9. PubMed ID: 21440623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interplay between MRP inhibition and metabolism of MRP inhibitors: the case of curcumin.
    Wortelboer HM; Usta M; van der Velde AE; Boersma MG; Spenkelink B; van Zanden JJ; Rietjens IM; van Bladeren PJ; Cnubben NH
    Chem Res Toxicol; 2003 Dec; 16(12):1642-51. PubMed ID: 14680379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.